Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Enzymatic DNA synthesis start-up Camena Bioscience gets $10 million in series A

by Laura Howes
July 9, 2023 | A version of this story appeared in Volume 101, Issue 22

 

The DNA synthesis start-up Camena Biosciences has closed its series A funding round with $10 million in its coffers, which it plans to use to scale its operations. The company says that the enzymatic-based DNA synthesis behind its gSynth platform can create 300 base-pair chains of synthetic DNA with 90% accuracy and that it has signed multiple commercial agreements to provide synthetic genes to customers.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.